The Coalition for Epidemic Preparedness Innovations will provide roughly $60 million [1] to accelerate the development of an Ebola vaccine.

This funding targets the Bundibugyo strain of the virus to curb the spread of the disease in the eastern Democratic Republic of Congo. Because different strains of Ebola require specific immunological responses, a targeted vaccine is necessary to prevent further fatalities in the region.

Moderna and two other groups, including the International Vaccine Institute (IAVI) and the University of Oxford, are the recipients of the funding [1]. The initiative aims to fast-track the creation of these medical countermeasures to respond to the ongoing outbreak in the eastern DRC [2].

The investment focuses on the specific challenges posed by the Bundibugyo strain, which differs from the more commonly known Zaire strain. By leveraging the expertise of Moderna and academic institutions, the coalition hopes to shorten the timeline from laboratory research to field deployment [3].

The allocation of $60 million [1] represents a coordinated effort between global health funders and biotechnology firms. The goal is to ensure that vaccine candidates can be rapidly tested and distributed as the outbreak continues to spread across Africa [4].

Public health officials said there is a need for a diverse portfolio of vaccines to handle various Ebola species. The partnership between private industry and university research is designed to maximize the speed of development and the scalability of production [3].

“CEPI will provide roughly $60 million to accelerate development of a vaccine.”

This investment signals a strategic shift toward preparing for specific, less common strains of Ebola rather than relying on a one-size-fits-all vaccine. By funding multiple groups including Moderna and Oxford, CEPI is diversifying its technical approach to ensure that at least one candidate succeeds in the face of an active outbreak in the DRC.